

July 2024 Student Formulary – Preventive Care Medications with \$0 Copay

Updates Effective 7/1/2024

U.S. Preventative Services Task Force A & B Recommendations

The Patient Protection and Affordable Care Act (PPACA) requires that certain health plans cover essential health benefits (EHB) without charging a copayment, coinsurance, or deductible. EHBs include a variety of preventative services and medications and are outlined by US Preventive Services Task Force (USPSTF) recommendations with an A or B rating. Based on the recommendations of USPSTF and the Centers for Disease Control and Prevention (CDC), Wellfleet Rx has identified preventative medications to be covered under the pharmacy benefit and updates this list of medications and coverage criteria as needed.

USPSTF and CDC recommendation updates can occur at any time, and health plans have specified timelines to implement these recommendations in compliance with federal law. Plans that meet the definition of a "grandfathered" plan are not subject to EHB requirements. State specific requirements may vary. Wellfleet Rx will monitor for ACA-related guidance and updates to ensure compliance with all regulations.

Standard EHB Zero Copay Table

All medications, including specified OTC items (e.g., aspirin, contraceptives, folic acid), included on the Wellfleet Rx EHB Zero Copay table are covered at zero copay if the member has a valid prescription; however, some medications are only covered at a zero copay for the population specified (e.g., specified age range). The table below contains the specific drug list contained in the EHB Zero Copay Table.

| Drug or Vaccine | Edit | Comments | |
|---------------------------------------|------------------------------|---|--|
| EHB Aspirin Drug List | | | |
| Aspirin | N/A | Generics only | |
| EHB Fluoride Drug List | | | |
| Fluoride | Age 6 months to 6 years | Generics only | |
| EHB Folic Acid Drug List | | | |
| Folic acid 0.4 mg, 0.8 mg, 1mg | N/A | Generics only | |
| EHB Contraceptives Drug List | | | |
| Oral and ring hormonal contraceptives | Step therapy (if applicable) | Generics and single-source brands (SSB) | |
| Transdermal contraceptives | N/A | Generics only (Xulane by Mylan) | |

Products, documents and materials provided by Wellfleet, including the material contained therein, are proprietary to Wellfleet Group, LLC and protected by applicable copyright or trade secrets laws. Information contained within may not be published, distributed, or reproduced, in part or whole, without express written consent of Wellfleet Group, LLC. Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC. All insurance products are administered or managed by Wellfleet Group, LLC. Product availability is based on regulatory approval and may differ among companies.



| Other contraceptive forms | • | Nexplanon: Limited to 1 per year Depo-Provera: Limited to 1 per 90 days | follo | vered products include the owing: Depo-Provera Liletta Mirena Nexplanon ParaGard Skyla Phexxi |
|--|------|---|-------|---|
| EHB Barrier Contraceptives Drug List | t | | | |
| Barrier contraceptives | • | Female condoms: 30 per 30 days | • | Cervical cap Diaphragms Nonoxynol 9 Female condoms |
| EHB Breast Cancer Prevention Drug | List | | | |
| RaloxifeneTamoxifenSoltamoxAnastrazoleExemestane | • | Anastrazole: Age ≥ 35 years; limited to 1 per day Exemestane: Age ≥ 35 years; limited to 1 per day Raloxifene: Limited to 1 per day | Brar | nds and generics |
| EHB Bowel Preparation Drug List | | | | |
| FDA-approved bowel preparations, including but not limited to the following: Bisacodyl Clenpiq PEG 3350 plus electrolytes (e.g., Colyte, Golytely, MoviPrep, Nulytely) Magnesium citrate Magnesium hydroxide OsmoPrep Plenvu Prepopik Sodium phosphate Suclear Suprep Sutab | | Age 45-75 years Quantity limit of 2 per year | Brar | nds and generics |



| EHB Pre-Diabetes Drug List | | |
|---|--|--|
| Metformin immediate-release tablets, extended-release tablets, and solution | | Generic products; for members aged 35 years or older who have been diagnosed with pre-diabetes |
| EHB HIV Pre-Exposure Prophylaxis (P | rEP) Drug List | |
| Descovy (emtricitabine/tenofovir alafenam) Truvada (emtricitabine, FTC/tenofovir disoproxil fumarate, TDF) Apretude (cabotegravir) extended-release injectable suspension | Descovy: Quantity limit of 1 tablet per day Generic Truvada: Quantity limit of 1 tablet per day Apretude: Quantity limit of 1 injection every 8 weeks No concurrent use of HIV medications for the treatment of HIV | N/A |
| EHB Statin Drug List | | |
| Low-moderate intensity statins Altoprev (lovastatin ER) 20-60 mg Crestor (rosuvastatin) 5-10 mg Ezallor Sprinkle (rosuvastatin) 5-10mg Flolipid (simvastatin suspension) 20mg/5mL, 40mg/5mL Lescol (fluvastatin) 20-40 mg, 40 mg twice daily Lescol XL (fluvastatin) 80 mg Lipitor (atorvastatin) 10-20 mg Livalo (pitavastatin calcium) 1-4 mg Mevacor (lovastatin) 20-40 mg Pravachol (pravastatin) 10-80 mg Zocor (simvastatin) 10-40 mg Zypitamag (pitavastatin magnesium) 1-4 mg | Age 40-75 years No concurrent use of secondary prevention medications* Quantity limited to statin dosages at low- to moderate-intensity Prior Authorization (Ezallor Sprinkle and Flolipid) Step Therapy (Altoprev, Ezallor Sprinkle, Lescol, Lescol XL, and Zypitamag) *Secondary prevention medications include: aspirin/dipyridamole clopidogrel dipyridamole nitroglycerin – oral, sublingual, transdermal, translingual prasugrel Praluent Repatha ticagrelor (Brilinta) ticlopidine vorapaxar (Zontivity) | Generics and Livalo |



| EHB Smoking Cessation Drug Lis | t | |
|--|--|--|
| bupropion (Zyban) | Age ≥ 18 yearsQuantity limit | Generic only |
| Varenicline (Chantix) | Age ≥ 18 yearsQuantity limit | Brand and generic |
| nicotine inhaler | Age ≥ 18 years Quantity limit Step Therapy: trial of nicotine transdermal patch required | OTC |
| nicotine spray | Age ≥ 18 years Quantity limit Step Therapy: trial of nicotine transdermal patch required | OTC |
| nicotine gum or lozenge | Age ≥ 18 yearsQuantity limit | OTC |
| nicotine transdermal patches | Age ≥ 18 yearsQuantity limit | OTC |
| EHB Vaccines – Influenza | | |
| Influenza vaccines | 1 dose per 180 days | Flublok, Fluzone High Dose, Fluzone Intradermal, and Fluad will continue to have adult age edits |
| EHB Vaccines – Other | | |
| COVID-19 Moderna [mRNA] [SpikeVax] Pfizer [mRNA] (Comirnaty) Novavax [Ad] | N/A | N/A |
| Diphtheria, tetanus, pertussis [DTaP] (Infanrix, Daptacel) | N/A | N/A |
| Diphtheria, tetanus, pertussis [DTaP]/Polio (Quadracel, Kinrix) | N/A | N/A |
| Diphtheria, tetanus, pertussis [DTaP]/Hepatitis B/Polio (Pediarix) | N/A | N/A |
| Diphtheria, tetanus, pertussis [DTaP]/ Polio/ Haemophilus influenzae type B/ Hepatitis B (Vaxelis) | N/A | N/A |



| Diphtheria, tetanus, pertussis [DTaP]/Polio/ Haemophilus influenzae type B (Pentacel) | N/A | N/A |
|---|--|-----|
| Human papillomavirus (Gardasil, Gardasil 9) | Age 9-45 years3 doses per 365 days | N/A |
| Hepatitis A (Vaqta, Havrix) | 2 doses per 365 days | N/A |
| Hepatitis B (Engerix-B, Recombivax HB, Heplisav-B) | 3 doses per 365 days (Engerix-B Adult; Recombivax HB) 2 doses per 365 days (Heplisav-B) | N/A |
| Hepatitis B/Hepatitis A combo (TwinRix) | Age ≥18 years4 doses per 365 days | N/A |
| Haemophilus influenzae type B (ActHIB, Hiberix, PedvaxHIB) | N/A | N/A |
| Japanese Encephalitis (Ixiaro) | N/A | N/A |
| Measles, mumps, rubella (M-M-R II, Priorix) | 2 doses per 365 days | N/A |
| Measles, mumps, rubella, varicella [MMRV](ProQuad) | N/A | N/A |
| Meningococcal serogroup B [MenB (Bexsero, Trumenba)] | Age 10-25 years2 doses per 365 days (Bexsero)3 doses per 365 days (Trumenba) | N/A |
| Meningococcal quadrivalent conjugate [MenACWY (Menactra, Menveo, MenQuadfi)] | Age 11-23 years, <u>unless required</u> <u>upon freshman admission</u> 1 dose per 365 days | N/A |
| Pneumococcal polysaccharide (Pneumovax 23) | 1 dose per 365 days Age ≥ 19 years, if immunocompromised | N/A |
| Pneumococcal conjugate (Prevnar 13, Prevnar 20, Vaxneuvance) | Prevnar 20, Vaxneuvance: Age ≥ 65 years Age ≥ 19 years, if immunocompromised | N/A |
| Poliovirus (Ipol) | N/A | N/A |
| Respiratory syncytial virus (Arexvy, Abrysvo) – new as of 1/1/24 | Arexvy: Age ≥ 60 years Abrysvo: Age ≥ 60 years OR in pregnant individuals between 32-36 weeks gestational age | N/A |
| Rotavirus (Rotarix, Rotateq) | N/A | N/A |



| Tetanus, diphtheria, pertussis [Tdap (Adacel, Boostrix)] | 1 dose per 365 days | N/A |
|--|--|-----|
| Tetanus, diphtheria [Td (Tenivac, Tdvax)] | 1 dose per 365 days | N/A |
| Varicella (Varivax) | 2 doses per 365 days | N/A |
| Zoster vaccine, recombinant (Shingrix) | Age ≥ 50 years Age ≥ 19 years, if immunocompromised 2 doses per 365 days | N/A |